HPTN 083 A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender

Grant

Date/time Interval

  • May 1, 2016 - May 31, 2017
  • Total Award Amount

  • 139431.00
  • Direct Costs

  • 98926.00
  • Sponsor Award Id

  • PO16002791